Among the diseases expected to be enriched in the CaG cohort given their established association with the French-Canadian founder effect, FXN and DMPK variants were identified at elevated frequencies, as anticipated. The high CF of FXN variants is consistent with the autosomal recessive nature of FRDA, in which carriers are unaffected and therefore not excluded during recruitment of CaG participants. The recent approval of omaveloxolone as a therapy for FRDA further increases the clinical value of identifying expansion carriers early in the Quebec population
![]() |

